Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)

Chemico-Biological Interactions

Volumn 234, Issue , 2015, Pages 339-348

  Zang, Tianzhu ^a   Verma, Kshitij ^b   Chen, Mo ^a   Jin, Yi ^a   Trippier, Paul C ^b,c   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

Author keywords

Androgen; Androgen receptor signaling; Castration resistant prostate cancer

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C2 PROTEIN, HUMAN; AKR1C3 PROTEIN, HUMAN; BACCHARIN; CINNAMIC ACID; CINNAMIC ACID DERIVATIVE; HYDROXYSTEROID DEHYDROGENASE; TRICHOTHECENE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION;

3-HYDROXYSTEROID DEHYDROGENASES; CINNAMATES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYDROXYSTEROID DEHYDROGENASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRICHOTHECENES;

EID: 84939990776     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.12.015     Document Type: Article

References (47)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics CA Cancer J. Clin. 64 2014 2014 9 29
2. H. Miyamoto, E.M. Messing, and C. Chang Androgen deprivation therapy for prostate cancer: current status and future prospects Prostate 61 2004 332 353
3. M.A. Perlmutter, and H. Lepor Androgen deprivation therapy in the treatment of advanced prostate cancer Rev. Urol. 9 Suppl. 1 2007 S3 S8
4. W.P. Harris, E.A. Mostaghel, P.S. Nelson, and B. Montgomery Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat. Clin. Pract. Urol. 6 2009 76 85
5. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, and C.C. Nelson Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res. 68 2008 6407 6415
6. T.M. Penning Androgen biosynthesis in castration-resistant prostate cancer Endocr. Relat. Cancer 21 2014 T67 T78
7. M. Bishr, and F. Saad Overview of the latest treatments for castration-resistant prostate cancer Nat. Rev. Urol. 10 2013 522 528
8. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
9. C.J. Logothetis, E. Efstathiou, F. Manuguid, and P. Kirkpatrick Abiraterone acetate Nat. Rev. Drug Discov. 10 2011 573 574
10. Y. Rehman, and J.E. Rosenberg Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer Drug Des Dev. Ther. 6 2012 13 18
11. C. Cai, S. Chen, P. Ng, G.J. Bubley, P.S. Nelson, E.A. Mostaghel, B. Marck, A.M. Matsumoto, N.I. Simon, H. Wang, S. Chen, and S.P. Balk Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res. 71 2011 6503 6513
12. E.A. Mostaghel, B.T. Marck, S.R. Plymate, R.L. Vessella, S. Balk, A.M. Matsumoto, P.S. Nelson, and R.B. Montgomery Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin. Cancer Res. 17 2011 5913 5925
13. A.O. Adeniji, M. Chen, and T.M. Penning AKR1C3 as a target in castrate resistant prostate cancer J. Steroid Biochem. Mol. Biol. 137 2013 136 149
14. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, J.D. Winkler, and T.M. Penning Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Bioorg. Med. Chem. Lett. 21 2011 1464 1468
15. M.C. Byrns, Y. Jin, and T.M. Penning Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights J. Steroid Biochem. Mol. Biol. 125 2011 95 104
16. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
17. J. Hofland, W.M. van Weerden, N.F. Dits, J. Steenbergen, G.J. van Leenders, G. Jenster, F.H. Schroder, and F.H. de Jong Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Res. 70 2010 1256 1264
18. M.J. Pfeiffer, F.P. Smit, J.P. Sedelaar, and J.A. Schalken Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer Mol. Med. 17 2011 657 664
19. A.R. Hamid, M.J. Pfeiffer, G.W. Verhaegh, E. Schaafsma, A. Brandt, F.C. Sweep, J.P. Sedelaar, and J.A. Schalken Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer Mol. Med. 18 2012 1449 1455
20. T.M. Downs, D.W. Burton, F.L. Araiza, R.H. Hastings, and L.J. Deftos PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3 Cancer Lett. 306 2011 52 59
21. M. Yepuru, Z. Wu, A. Kulkarni, F. Yin, C.M. Barrett, J. Kim, M.S. Steiner, D.D. Miller, J.T. Dalton, and R. Narayanan Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth Clin. Cancer Res. 19 2013 5613 5625
22. Y.D. Yin, M. Fu, D.G. Brooke, D.M. Heinrich, W.A. Denny, and S.M. Jamieson The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17β-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer Front. Oncol. 4 2014 159
23. P. Bydal, V. Luu-The, F. Labrie, and D. Poirier Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities Eur. J. Med. Chem. 44 2009 632 644
24. D.R. Bauman, S.I. Rudnick, L.M. Szewczuk, Y. Jin, S. Gopishetty, and T.M. Penning Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes Mol. Pharmacol. 67 2005 60 68
25. M.C. Byrns, S. Steckelbroeck, and T.M. Penning An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochem. Pharmacol. 75 2008 484 493
26. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, M. Chen, J.D. Winkler, and T.M. Penning Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships J. Med. Chem. 55 2012 2311 2323
27. M.C. Byrns, and T.M. Penning Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs Chem. Biol. Interact. 178 2009 221 227
28. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 351 2000 67 77
29. S. Steckelbroeck, Y. Jin, S. Gopishetty, B. Oyesanmi, and T.M. Penning Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action J. Biol. Chem. 279 2004 10784 10795
30. Y. Akao, H. Maruyama, K. Matsumoto, K. Ohguchi, K. Nishizawa, T. Sakamoto, Y. Araki, S. Mishima, and Y. Nozawa Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines Biol. Pharm. Bull. 26 2003 1057 1059
31. S. Mishima, Y. Ono, Y. Araki, Y. Akao, and Y. Nozawa Two related cinnamic acid derivatives from Brazilian honey bee propolis, baccharin and drupanin, induce growth inhibition in allografted sarcoma S-180 in mice Biol. Pharm. Bull. 28 2005 1025 1030
32. S.H. Cestari, J.K. Bastos, and L.C. Di Stasi Intestinal anti-inflammatory activity of Baccharis dracunculifolia in the trinitrobenzenesulphonic acid model of rat colitis Evid. Based Complement. Altern. Med. 2011 2011 524349
33. E.W. Teixeira, D. Message, G. Negri, A. Salatino, and P.C. Stringheta Seasonal variation, chemical composition and antioxidant activity of Brazilian propolis samples Evid. Based Complement. Altern. Med. 7 2010 307 315
34. P. De, M. Baltas, and F. Bedos-Belval Cinnamic acid derivatives as anticancer agents - a review Curr. Med. Chem. 18 2011 1672 1703
35. A. Jitareanu, G. Tataringa, A.M. Zbancioc, C. Tuchilus, and U. Stanescu Antimicrobial activity of some cinnamic acid derivatives Rev. Med. Chir. Soc. Med. Nat. Iasi 115 2011 965 971
36. G.A. Burdock Review of the biological properties and toxicity of bee propolis (propolis) Food Chem. Toxicol. 36 1998 347 363
37. S. Endo, T. Matsunaga, A. Kanamori, Y. Otsuji, H. Nagai, K. Sundaram, O. El-Kabbani, N. Toyooka, S. Ohta, and A. Hara Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis J. Nat. Prod. 75 2012 716 721
38. H. Tani, K. Hasumi, T. Tatefuji, K. Hashimoto, H. Koshino, and S. Takahashi Inhibitory activity of Brazilian green propolis components and their derivatives on the release of cys-leukotrienes Bioorg. Med. Chem. 18 2010 151 157
39. A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, D.W. Christianson, L.J. Marnett, and T.M. Penning Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer J. Med. Chem. 56 2013 2429 2446
40. A. Kurek-Gorecka, A. Rzepecka-Stojko, M. Gorecki, J. Stojko, M. Sosada, and G. Swierczek-Zieba Structure and antioxidant activity of polyphenols derived from propolis Molecules 19 2013 78 101
41. M. Gazvoda, N. Beranic, S. Turk, B. Burja, M. Kocevar, T.L. Rizner, S. Gobec, and S. Polanc 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) Eur. J. Med. Chem. 62 2013 89 97
42. D.M. Heinrich, J.U. Flanagan, S.M. Jamieson, S. Silva, L.J. Rigoreau, E. Trivier, T. Raynham, A.P. Turnbull, and W.A. Denny Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3 Eur. J. Med. Chem. 62 2013 738 744
43. P. Brozic, S. Turk, A.O. Adeniji, J. Konc, D. Janezic, T.M. Penning, T. Lanisnik Rizner, and S. Gobec Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library J. Med. Chem. 55 2012 7417 7424
44. S.M. Jamieson, D.G. Brooke, D. Heinrich, G.J. Atwell, S. Silva, E.J. Hamilton, A.P. Turnbull, L.J. Rigoreau, E. Trivier, C. Soudy, S.S. Samlal, P.J. Owen, E. Schroeder, T. Raynham, J.U. Flanagan, and W.A. Denny 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly potent and selective inhibitors of the type 5 17β-hydroxysteroid dehydrogenase AKR1C3 J. Med. Chem. 55 2012 7746 7758
45. M. Sinreih, I. Sosic, N. Beranic, S. Turk, A.O. Adeniji, T.M. Penning, T.L. Rizner, and S. Gobec N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3 Bioorg. Med. Chem. Lett. 22 2012 5948 5951
46. P. Brozic, B. Golob, N. Gomboc, T.L. Rizner, and S. Gobec Cinnamic acids as new inhibitors of 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) Mol. Cell. Endocrinol. 248 2006 233 235
47. S. Endo, D. Hu, T. Matsunaga, Y. Otsuji, O. El-Kabbani, M. Kandeel, A. Ikari, A. Hara, Y. Kitade, and N. Toyooka Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3 Bioorg. Med. Chem. 2014